Oral vinorelbine -: Role in the management of metastatic breast cancer
Oral vinorelbine -: Role in the management of metastatic breast cancer
复制标题
DOI：
10.2165/00003495-200767050-00002
复制
发表时间：
2007-01-01
期刊：
影响因子：
11.5
通讯作者：
Trillet-Lenoir, Veronique
中科院分区：
文献类型：
--
作者：
Aapro, Matti S.;Conte, Pierfranco;Trillet-Lenoir, Veronique
晚期乳腺癌的治疗正在不断发展，目的是提高缓解的质量和持续时间，在某些情况下，提高生存率。在这种情况下，生活质量的重要性不容低估，人们越来越关注治疗的便利性和依从性。新的抗癌药物已经提高了疗效，但对于其中许多药物来说，毒性往往仍然是一个问题。长春瑞滨似乎是转移性乳腺癌的一种有效且耐受性良好的治疗方法。特别地，口服制剂具有与注射制剂相似的功效，并且已经显示出总体上有利的耐受性，患者和医生都高度接受。这种和其他新型、耐受性良好和有效的治疗方法的可用性为定制治疗以满足个体患者需求提供了更大的潜力，因此也提供了改善患者结局的潜力。初步数据表明，口服长春瑞滨可能允许持续，有效的化疗时，进一步的肠外治疗更密集和毒性更大的药物被认为是不合适的。早期研究结果还表明，口服长春瑞滨，当与另一种新的口服药物，卡培他滨，可能是一个有效的选择，在转移性乳腺癌治疗。此外，长春瑞滨加单克隆抗体曲妥珠单抗，有或没有口服卡培他滨，似乎是另一种方案，可能是值得进一步研究的人表皮生长因子-2阳性晚期乳腺癌患者。
The treatment of advanced breast cancer is continually evolving, with the aim of improving the quality and duration of remission and, in some instances, survival. In this setting, the importance of quality of life cannot be underestimated, and growing attention is being paid to treatment convenience and compliance. New anticancer agents have improved efficacy, but for many of them, toxicity often remains a problem. Vinorelbine seems to represent both an active and a well tolerated treatment for metastatic breast cancer. In particular, the oral formulation has similar efficacy to that of the injectable formulation and has demonstrated generally favourable tolerability, with a high degree of acceptance by both patients and physicians. The availability of this and other novel, well tolerated and effective treatments provides greater potential to tailor treatment to meet individual patient needs and, therefore, also provide the potential to improve patient outcomes. Preliminary data suggest that oral vinorelbine may permit continued, effective chemotherapy when further parenteral therapy with more intensive and more toxic agents is considered inappropriate. Early findings also suggest that oral vinorelbine, when administered together with another new oral agent, capecitabine, may be a valid choice in metastatic breast cancer treatment. Furthermore, vinorelbine plus the monoclonal antibody trastuzumab, with or without oral capecitabine, appears to be another regimen that may be worthy of additional study in patients with human epidermal growth factor-2 positive advanced breast cancer.